Eiji Tahara, President and CEO
Working on the frontier of pre-symptomatic and early-stage disease detection: MiRTeL’s CEO discusses the importance of continuous testing for disease prevention
In Japan, health care costs consistently increase annually. Based on data released on September 13th of this year, the Japanese Ministry of Health, Labour, and Welfare estimates that the national health care costs were approximately ¥42.3644 trillion for 2015, and by 2025, they are predicted to increase to ¥60 trillion.
Thus, the reduction of health care costs is an urgent issue for Japan. The question is: what is the most effective approach? An answer lies in disease prevention and early-stage diagnosis. Although it is critical to achieve physical health to avoid becoming easily ill, early-stage detection, in the event that one does nevertheless contract a disease, reduces the risk of requiring long-term treatment. Hence, it can reduce health care costs.
There has recently been great interest in disease prevention and early-stage detection, and MiRTeL Co. is working on a new frontier in testing technologies that enable early risk prediction for cancer and dementia.
Eiji Tahara, MiRTeL’s President and CEO, states that “The market relating to pre-symptomatic prophylaxis is expected to expand to ¥10 trillion in 2020, and the demand for continuous testing for disease prevention is also expected to increase.”
In 2001, Eiji Tahara was awarded a PhD in pharmacology by Hiroshima University’s Graduate School of Medical Sciences. Subsequently, he worked as a researcher in the New Drug Discovery Laboratory, Wakunaga Pharmaceutical Co. Ltd., in areas such as improving biodiagnostic agents, involving HLA typing. Then, for two years from 2005 he worked in cancer research as a visiting scientist at MD Anderson Cancer Center in the United States. Next, after being appointed Vice Senior Researcher by the Drug Discovery Laboratory at Wakunaga Pharmaceutical Co. Ltd., he was active as the R&D Manager for Wakunaga of America Co., Ltd., at sites in 50 different countries. After leaving Wakunaga in 2013, he joined the Business Development Department of MiRTeL, and was appointed President and CEO the following year. He is also a frequent special lecturer in human cultural studies and functional nutritional diseases at the Prefectural University of Hiroshima Graduate School.
MiRTeL was established as a Hiroshima University venture company in 2012, and business activities with MiRTeL® tests were launched in 2013.
The company’s aims are to reduce disease risk by prevention, based on the telomere test, and to detect and diagnose disease at a very early stage using the MiR test, enabling prompt treatment to achieve a healthy aging society.
We provide total business support through our Business Development Office, our Tokyo 21c Club of members from a wide range of industries and our highly experienced management team.